Interleukin-1 beta (IL-1 beta)
Ultrasensitive Immunoassay
Rules-Based Medicine’s (RBM) internally developed and manufactured ultrasensitive immunoassay to interleukin-1 beta (IL-1b) based on the Simoa® bead technology can accurately quantitate sub-pg/mL levels of IL-1b in human plasma and serum. The Simoa IL-1b assay is a valuable clinical research tool for pharmacodynamic analysis of inflammatory, autoimmune, cancer, neurodegenerative, and infectious diseases.
IL-1b is a member of the interleukin 1 family of cytokines and is primarily involved in the regulation of immune and inflammatory responses. It is produced by many cells including macrophage, NK cells, monocytes, and neutrophils. IL-1b is involved in regulating cellular activities, such as cell proliferation, differentiation, and apoptosis. It is produced as an inactive 31 kDa precursor (pro-IL-1β), which is proteolytically processed to its active form by caspase 1. Induction of pro-IL-1β expression is inefficient for the secretion of the cytokine. The biological activities of IL-1β is mediated by binding to type 1 IL-1 receptor. IL-1b is also important for the regulation of adaptive immune responses by inducing the differentiation of type 17 T-helper cells and the production of IL-17. The systemic effects of IL-1b includes hypotension, fever and neutrophilia.
While IL-1b is essential for host-response and resistance to pathogens, it also exacerbate damage during chronic disease and acute tissue injury. Serum IL-1b are elevated in patients with heart disease, including atherosclerosis, angina, and myocardial infarction. IL-1b blocking agents have been found to be effective in the treatment of several inflammatory and autoimmune diseases including rheumatoid arthritis, ischemic stroke, hemorrhagic stroke, diabetes. uveitis, autoimmune thyroid diseases, multiple sclerosis, and myocarditis.
Swiss-Prot Accession Number: P01584
| Biomarker | LLOQ* (Serum and Plasma) |
LLOQ* (Undiluted Samples) |
Volume Required | |
|---|---|---|---|---|
| Serum or plasma | Other fluids** | |||
| Interleukin-1 beta (IL-1 beta) | 0.031 pg/mL | 0.016 pg/mL | 150 µL | 150 µL |
* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.
** Cerebrospinal fluid, urine, tissue culture supernatants, bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.
All assay services are performed in our CLIA-certified laboratory.
Intended for Research Use Only.